eFFECTOR Therapeutics Inc (EFTR)

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.35% - MSN

MSN

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance

Yahoo Finance

eFFECTOR Therapeutics (NASDAQ:EFTR) Trading Up 1.5% - Defense World

Defense World

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance

Yahoo Finance

Head to Head Survey: eFFECTOR Therapeutics (NASDAQ:EFTR) versus COMPASS Pathways (NASDAQ:CMPS) - Defense World

Defense World

eFFECTOR Therapeutics to Participate in Upcoming Investor Conference

GlobeNewswire Inc.

eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails

Zacks Investment Research

eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails - Zacks Investment Research

Zacks Investment Research

Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results

Benzinga

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings

Benzinga

Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000

Benzinga

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

GlobeNewswire Inc.

Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000 - Allurion Technologies (NYSE:ALUR), eFF - Benzinga

Benzinga

Effector Therapeutics' Stock Issuance Capped: Navigating the Lincoln Park Agreement's Exchange Limit - TipRanks.com - TipRanks

TipRanks

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance

Yahoo Finance

eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire Inc.

Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?

Zacks Investment Research

Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect? - Yahoo Finance

Yahoo Finance

eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire Inc.

eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under ... - Yahoo Finance

Yahoo Finance

(EFTR) Investment Analysis and Advice - Stock Traders Daily

Stock Traders Daily

Dow Tumbles Over 200 Points; US Trade Gap Narrows In November

Benzinga

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024

GlobeNewswire Inc.

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024 - GlobeNewswire

GlobeNewswire

Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket

Benzinga

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket - Markets Insider

Markets Insider

eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients

GlobeNewswire Inc.

eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts ... - Yahoo Finance

Yahoo Finance

The role of STRIs in cancer - Drug Target Review

Drug Target Review

eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Yahoo Finance

Yahoo Finance

BioTechnology Innovators Honored in 3rd Annual BioTech Breakthrough Awards Program - GlobeNewswire

GlobeNewswire

3 Promising Biotech Stocks That Will Make Early Investors Rich - InvestorPlace

InvestorPlace

eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire

GlobeNewswire

ASCO 2023 – Deep And Early Responses Lift Hopes At Effector - Scrip

Scrip

Investors in eFFECTOR Therapeutics (NASDAQ:EFTR) from a year ago are still down 35%, even after 77% gain this ... - Yahoo Finance

Yahoo Finance

Why Is eFFECTOR Therapeutics (EFTR) Stock Up 75% Today? - InvestorPlace

InvestorPlace

3 Penny Stocks That Could Turn $1000 into $10000 in a Year - InvestorPlace

InvestorPlace

eFFECTOR Therapeutics Shares Fall After Data From COVID-19 Treatment Trial - Yahoo Finance

Yahoo Finance

eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference - Yahoo Finance

Yahoo Finance

eFFECTOR Therapeutics Shares Jump After Clinical Update Of Investigational Cancer Drug - Yahoo Finance

Yahoo Finance

First Patient With Lung Cancer Treated in Phase 2b Tomivosertib Trial - Curetoday.com

Curetoday.com

EFTR Stock Price and Chart — NASDAQ:EFTR — TradingView - TradingView

TradingView

What's Going On With eFFECTOR Therapeutics Stock Today? - Yahoo Finance

Yahoo Finance

SPAC Attack: The 10 biggest in biotech - Fierce Biotech

Fierce Biotech

eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis - MarketBeat

MarketBeat

Press Release Distribution and Management - GlobeNewswire

GlobeNewswire